AstraZeneca Executive and Leadership Team

Aradhana Sarin, the Executive Director & Chief Financial Officer at AstraZeneca, directs the global financial architecture and capital allocation strategies. Overseeing the fiscal health of the organization, the Executive Director & Chief Financial Officer ensures alignment between investment in oncology research and long-term shareholder value. This leadership role involves managing complex balance sheets while supporting the discovery of prescription medicines. By optimizing resource distribution across cardiovascular and respiratory portfolios, Aradhana Sarin directly impacts the company's ability to fund high-stakes clinical trials. Sarin maintains rigorous oversight of financial reporting standards, ensuring transparency across international markets. Through disciplined fiscal management, the Executive Director & Chief Financial Officer secures the necessary capital to sustain the pipeline of innovative therapies, ultimately driving the commercial success of the enterprise within the competitive global pharmaceutical landscape.

Santiago Rivera, the Chief Financial Officer & Chief Financial Officer, Andean Cluster at AstraZeneca, manages regional financial operations and strategic planning within the Andean market. Overseeing the economic performance of the cluster, the Chief Financial Officer & Chief Financial Officer, Andean Cluster ensures that local commercial activities support the broader corporate mission of delivering life-changing medicines. This leadership role involves navigating complex regulatory environments and currency fluctuations to maintain profitability. By implementing robust financial controls, Santiago Rivera optimizes the supply chain and distribution efficiency for prescription drugs across the region. Rivera coordinates with global finance teams to integrate regional data into the overarching corporate strategy. Through precise forecasting and risk management, the Chief Financial Officer & Chief Financial Officer, Andean Cluster sustains the growth of the biopharmaceutical portfolio, ensuring that the company remains a leader in the regional healthcare market.

Aaron Kroft, the Chief Financial Officer, Enterprise Cell Therapy Unit at AstraZeneca, manages the financial strategy for the specialized cell therapy division. Overseeing the investment in cutting-edge biotechnology, the Chief Financial Officer, Enterprise Cell Therapy Unit ensures that the unit maintains a sustainable path toward commercial viability. This leadership role involves evaluating the cost-benefit analysis of complex manufacturing processes and clinical development programs. By providing financial oversight for high-growth therapeutic areas, Aaron Kroft enables the rapid scaling of cell therapy capabilities. Kroft collaborates with research leads to prioritize projects that offer the highest potential for patient impact. Through meticulous budget management and strategic planning, the Chief Financial Officer, Enterprise Cell Therapy Unit supports the company's mission to revolutionize treatment paradigms, ensuring that the enterprise remains at the forefront of medical science and therapeutic innovation.

Joey Zhu, the Chief Financial Officer, PA To The at AstraZeneca, manages administrative financial workflows and executive support operations. Overseeing the fiscal coordination of high-level administrative functions, the Chief Financial Officer, PA To The ensures that executive leadership possesses the resources required for effective decision-making. This leadership role involves streamlining the financial processes that support the office of the executive, ensuring that operational costs remain aligned with corporate efficiency goals. By managing the intersection of administrative logistics and financial oversight, Joey Zhu facilitates the smooth execution of corporate strategy. Zhu coordinates with various departments to ensure that financial reporting for administrative projects remains accurate and timely. Through the optimization of internal support systems, the Chief Financial Officer, PA To The contributes to the overall operational excellence of the company, allowing the leadership team to focus on the core mission of developing life-changing prescription medicines.

Mariam Selim, the Chief Financial Officer, Cluster Near & Maghreb (East) at AstraZeneca, directs the financial operations across the Near and Maghreb regions. Overseeing the regional fiscal strategy, the Chief Financial Officer, Cluster Near & Maghreb (East) ensures that commercial activities align with the company's global standards for growth and compliance. This leadership role involves managing regional budgets and navigating the unique economic landscapes of the cluster to support the distribution of prescription medicines. By implementing localized financial strategies, Mariam Selim optimizes the performance of the cardiovascular and respiratory portfolios in the region. Selim coordinates with global finance to ensure that regional outcomes contribute positively to the overall corporate balance sheet. Through rigorous financial oversight and strategic planning, the Chief Financial Officer, Cluster Near & Maghreb (East) sustains the company's market presence, ensuring that patients in the region receive access to essential therapeutic solutions.

Gonzalo Kuri, the Chief Financial Officer, LATAM at AstraZeneca, manages the financial health and strategic direction of the Latin American operations. Overseeing the fiscal performance of the region, the Chief Financial Officer, LATAM ensures that the company effectively commercializes its portfolio of prescription medicines across diverse markets. This leadership role involves managing regional investment strategies and mitigating financial risks associated with volatile economic environments. By optimizing the allocation of resources, Gonzalo Kuri supports the expansion of the company's footprint in oncology and biopharmaceuticals. Kuri collaborates with regional leadership to drive revenue growth and operational efficiency. Through the implementation of robust financial frameworks, the Chief Financial Officer, LATAM ensures that the company maintains a competitive edge in the region, ultimately supporting the mission to deliver innovative healthcare solutions to patients throughout Latin America while maintaining strict adherence to corporate financial policies.

Kevin Durning, the Chief Financial Officer (US) & Vice President, Finance Biopharmaceuticals at AstraZeneca, manages the financial strategy for the United States market and the global biopharmaceuticals division. Overseeing the fiscal performance of the largest market, the Chief Financial Officer (US) & Vice President, Finance Biopharmaceuticals ensures that the company achieves its revenue targets while maintaining cost discipline. This leadership role involves analyzing market trends and allocating capital to support the commercialization of cardiovascular, renal, and metabolism medicines. By providing financial leadership, Kevin Durning enables the company to navigate the complexities of the US healthcare system. Durning collaborates with the board to ensure that financial objectives support the long-term growth of the biopharmaceutical portfolio. Through precise financial planning and performance management, the Chief Financial Officer (US) & Vice President, Finance Biopharmaceuticals secures the company's market leadership, ensuring that patients have access to life-saving treatments.

Jennifer Givens, the Management Director, Operations & Chief Operating Officer, Oncology Research & Development at AstraZeneca, architects the operational framework for the oncology pipeline. Overseeing the integration of research and development workflows, the Management Director, Operations & Chief Operating Officer, Oncology Research & Development ensures that clinical trials proceed with maximum efficiency. This leadership role involves streamlining laboratory processes and accelerating the transition from discovery to commercialization. By aligning cross-functional teams, Jennifer Givens drives the development of next-generation cancer therapies. Givens manages the logistical complexities of global research initiatives, ensuring that scientific breakthroughs reach patients rapidly. Through the implementation of advanced operational metrics, the Management Director, Operations & Chief Operating Officer, Oncology Research & Development optimizes the allocation of research talent and infrastructure, directly supporting the company's position as a pioneer in oncology and life-saving medical innovation.

Renee Iacona, the Chief Operating Officer, Oncology Research & Development at AstraZeneca, directs the operational execution of the oncology research pipeline. Overseeing the day-to-day activities of the research teams, the Chief Operating Officer, Oncology Research & Development ensures that scientific projects remain on schedule and within budget. This leadership role involves managing the infrastructure required for complex clinical research and fostering collaboration between laboratory scientists and clinical trial managers. By streamlining the research process, Renee Iacona accelerates the development of new cancer treatments. Iacona coordinates with other C-suite leaders to ensure that the oncology strategy aligns with the company's broader commercial goals. Through the application of rigorous operational standards, the Chief Operating Officer, Oncology Research & Development optimizes the productivity of the research division, ensuring that the company continues to deliver breakthrough therapies that address critical unmet needs in the global oncology market.

Monique Zafirovski, the Global HR Business Partner & Chief of Staff at AstraZeneca, directs the organizational culture and human capital strategy. Overseeing the alignment of talent management with corporate objectives, the Global HR Business Partner & Chief of Staff ensures that the workforce remains focused on the discovery and development of prescription medicines. This leadership role involves coordinating executive communications and facilitating strategic initiatives across the global organization. By fostering an environment of innovation and inclusion, Monique Zafirovski supports the retention of top-tier scientific and operational talent. Zafirovski manages the intersection of human resources and executive decision-making, ensuring that leadership priorities are effectively communicated and executed. Through the development of robust talent pipelines, the Global HR Business Partner & Chief of Staff strengthens the company's ability to deliver on its mission, ensuring that the organization possesses the human capital necessary to lead in the pharmaceutical industry.